(AQB) AquaBounty Technologies, Inc. VRIO Analysis Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(AQB) AquaBounty Technologies, Inc. Complete Analysis Pack
AquaBounty VRIO: Where Its Competitive Edge Really Comes From
Unlock AquaBounty Technologies, Inc.’s strategic edge with our full VRIO Analysis—one concise, actionable file that maps which resources deliver value, rarity, imitability, and organizational support, and pinpoints where the company can sustain advantage versus peers; ideal for investors, analysts, consultants, and strategists seeking practical, ready-to-use insight.
AquAdvantage salmon intellectual property
Value
AquaBounty Technologies, Inc.'s AquAdvantage salmon IP is valuable because its proprietary growth gene and patent cover the faster-growth trait, which helped secure the FDA's first approval for a genetically engineered food animal in 2015. That protection supports premium positioning and can block direct copies of the trait.
Rarity
AquAdvantage salmon is rare because fish-biotech approvals are still unusually scarce and slow: AquaBounty Technologies, Inc. spent about 20 years getting U.S. and Canadian clearance for a single engineered fish. That regulatory barrier makes the IP hard to copy and gives the patented salmon trait scarcity value.
Imitability
AquAdvantage salmon is hard to copy because the IP depends on years of genetic work, fish-health data, and specialized bioprocess talent, not just a single patent. Even if a rival could see the end product, matching AquaBounty Technologies, Inc.'s breeding controls, regulatory know-how, and sustained R&D spend would still take heavy time and capital.
Organization
AquaBounty Technologies, Inc. has real know-how in contained production: its Albany, Indiana recirculating aquaculture system was built for about 1,200 metric tons of salmon a year, and the company also ran the Bay Fortune, Prince Edward Island facility. That operating history supports organizational strength in AquAdvantage salmon IP because the model depends on controlled, land-based production.
Competitive Advantage
AquAdvantage salmon IP gives AquaBounty Technologies, Inc. a temporary competitive advantage because the FDA approved it as the first genetically engineered animal for food in 2015, so the brand and process know-how still create a market lead. But patents, regulatory know-how, and production scale can be copied or caught up with over time, so the edge is real but not durable.
A Rare, Defensible Edge in Genetically Engineered Salmon
AquAdvantage salmon IP is valuable and rare because AquaBounty Technologies, Inc. owns the growth-gene and regulatory package behind the first FDA-approved genetically engineered food animal, approved in 2015 after about 20 years of work. That mix of patents, approvals, and contained-production know-how is hard to copy, but the edge is still time-limited as rivals can catch up.
| Metric | Data |
|---|---|
| FDA approval | 2015 |
| Development time | ~20 years |
| Almighty capacity | 1,200 metric tons/year |
What is included in the product
Detailed Word Document
A concise VRIO view of AquaBounty’s key resources, showing which capabilities are valuable, rare, hard to copy, and well organized.
Customizable Excel Spreadsheet
Helps users quickly spot AquaBounty’s key resources, competitive edge, and defensibility without building a VRIO from scratch.
Reference Sources
Shows which AquaBounty resources are valuable, rare, hard to imitate, and organizationally supported to judge real competitive advantage.
Regulatory approvals and compliance expertise
Value
AquaBounty Technologies, Inc. won FDA approval for AquAdvantage salmon in 2015 and Health Canada approval in 2016, and its patented growth-gene construct and production method protect the fast-growing trait. That IP moat supports premium differentiation, even as the company reported no product revenue in 2024 after closing its Indiana farm.
Rarity
Regulatory approvals are rare in fish biotech: AquaBounty Technologies, Inc. needed about 25 years to win FDA approval for AquAdvantage Salmon in 2015, and Canada followed in 2016. That long path shows why this expertise is scarce and hard to copy, especially after years of food-safety, environmental, and labeling review.
Imitability
AquaBounty Technologies, Inc. has a hard-to-copy edge here: its AquAdvantage salmon secured FDA approval in 2015 and Health Canada approval in 2016, and that kind of regulatory dossier takes years of specialist work, testing, and documentation. Rebuilding the same compliance know-how needs rare talent, deep data sets, and steady funding, so rivals face a long and costly path.
Organization
AquaBounty Technologies, Inc. built know-how in contained production facilities through its recirculating aquaculture system sites in Bay Fortune, Prince Edward Island, and Pioneer, Ohio. That operating model mattered: the U.S. FDA approved AquAdvantage salmon in 2015, and the company’s 2024 Form 10-K reported just $4.3 million in cash and cash equivalents, showing how hard compliance and facility control are to sustain.
Competitive Advantage
AquaBounty Technologies, Inc. had a temporary edge from its FDA approval for AquaAdvantage salmon, the first genetically engineered animal food approved by the U.S. FDA in 2015 after a 20-year review. But that moat was short-lived: by 2024 the Company had only 1 operating hatchery and 0 commercial sales from its U.S. farm, showing regulatory know-how helps, yet it does not stay rare for long.
A Rare Regulatory Edge, But No Revenue to Show for It
Regulatory approvals gave AquaBounty Technologies, Inc. a rare edge: AquAdvantage salmon won FDA approval in 2015 and Health Canada approval in 2016 after about 25 years of review. That compliance skill is hard to copy, but it did not drive current scale, as the company reported $0 product revenue in 2024 and only $4.3 million cash.
| Metric | Value |
|---|---|
| FDA approval | 2015 |
| Health Canada approval | 2016 |
| Review time | About 25 years |
| 2024 product revenue | $0 |
| 2024 cash | $4.3 million |
Preview Before You Purchase
VRIO Analysis
The document you're previewing is the actual AquaBounty Technologies, Inc. VRIO Analysis—not a mockup. When you purchase, you'll receive this same professional file in full, formatted and ready to edit, present, or share, with no hidden content or surprises.
Genetics, genomics, and fish-health R&D capability
Value
AquaBounty Technologies, Inc.'s value comes from its protected AquAdvantage salmon trait: the first FDA-approved genetically engineered animal for food in 2015. That patent-backed growth-hormone construct, plus fish-health R&D, helps defend premium differentiation and entry barriers.
Rarity
AquaBounty Technologies, Inc. holds a rare R&D edge because fish-biotech approvals are still scarce and slow: AquaAdvantage salmon took about 20 years to clear the U.S. FDA, from the 1995 filing to the 2015 approval. That kind of barrier is hard to copy, since very few genetically engineered fish have reached food-market approval at all.
Imitability
Imitability is low: AquaBounty Technologies, Inc.’s genetics, genomics, and fish-health R&D depends on scarce specialists, proprietary datasets, and years of trial-and-error work that rivals cannot quickly copy. In its latest FY2025 filings, the company still showed heavy R&D dependence, which signals that this capability is built through sustained spending, not bought off the shelf.
Organization
AquaBounty Technologies, Inc. built organization know-how around 2 contained production facilities, so its genetics and fish-health R&D could be moved into controlled farm operations rather than staying at lab level. That operating discipline mattered most when scaling AquAdvantage salmon, where biosecurity and fish performance had to work together.
Competitive Advantage
AquaBounty Technologies, Inc. built value through its genetics, genomics, and fish-health R&D, highlighted by FDA approval of AquAdvantage salmon in 2015. That edge was real but temporary, because the know-how can be narrowed by patents expiring, rivals copying methods, and regulators approving similar traits over time.
AquaBounty’s R&D Edge: 20 Years to FDA Approval
AquaBounty Technologies, Inc.'s genetics, genomics, and fish-health R&D is valuable because it helped create AquAdvantage salmon, the first FDA-approved genetically engineered animal for food in 2015. The edge is hard to copy, but it depends on sustained R&D spending, scarce specialists, and regulatory know-how.
| Metric | Data |
|---|---|
| FDA approval | 2015 |
| Time to approval | About 20 years |
Land-based recirculating aquaculture system know-how
Value
AquaBounty Technologies, Inc. has high Value here because its proprietary genes and patents protect the fast-growing salmon trait, making imitation harder and supporting premium pricing. The moat is still thin in scale, though: the company’s public filings show a small revenue base and ongoing losses, so the IP matters most as a differentiation tool, not a volume engine.
Rarity
Rarity is high because land-based recirculating aquaculture system know-how in fish biotech sits behind long, costly approvals. AquaBounty’s genetically engineered salmon took about 20 years from the 2001 FDA filing to the 2021 U.S. approval, showing how scarce and slow this expertise is.
Imitability
AquaBounty Technologies, Inc.’s land-based recirculating aquaculture system know-how is hard to copy because it blends biotech, water-treatment, fish-health, and process control skills that take years to build. The moat depends on specialized staff, operating data, and repeated capital spending on tanks, filtration, and biosecurity, so rivals cannot clone it quickly.
Organization
AquaBounty Technologies, Inc. has real know-how in designing and running land-based recirculating aquaculture systems, built through its contained salmon facilities in Canada and the U.S. That operating playbook is hard to copy, but in 2025 the company’s asset base was under pressure as it wound down operations, so the know-how had value but limited current use.
Competitive Advantage
AquaBounty Technologies, Inc.’s land-based recirculating aquaculture system know-how gives it a temporary competitive advantage: the Company has spent years refining water filtration, biosecurity, and fish-health controls that are hard to copy fast. Still, RAS expertise is imitable over time, and AquaBounty Technologies, Inc. has not shown a durable scale edge, so the benefit is real but likely short-lived.
Rare Salmon Know-How, But Little 2025 Scale Value
AquaBounty Technologies, Inc.’s land-based recirculating aquaculture system know-how is valuable and hard to copy because it combines water treatment, biosecurity, fish health, and process control built over years of contained salmon operations. But in 2025 the Company was winding down operations, so the know-how had little active scale value despite being scarce.
| Metric | Data |
|---|---|
| FDA approval timeline | 2001 to 2021 |
| 2025 operating state | Winding down |
| Business impact | Hard to copy, limited use |
Broodstock, hatchery, egg, and fry production capability
Value
AquaBounty Technologies, Inc.’s broodstock and hatchery asset base is valuable because its patented AquAdvantage salmon grows to market size in about 19 months, versus about 28 to 36 months for conventional Atlantic salmon. That trait, protected by proprietary genes and patents, supports premium pricing and a clear product gap in a market where global salmon supply is still tight.
Rarity
AquaBounty Technologies, Inc.'s broodstock, hatchery, egg, and fry production is rare because fish-biotech approvals are unusually scarce and slow: the U.S. FDA approved AquAdvantage Salmon only in 2015, after more than 20 years of review, and it was the first genetically engineered animal cleared for food. That long, high-bar process makes approved egg-to-fry capacity hard to copy.
Imitability
Imitability is low because AquaBounty Technologies, Inc.'s broodstock, hatchery, egg, and fry production depends on more than 20 years of breeding data, specialized biosecurity know-how, and tightly managed incubation systems. That mix is hard to copy fast, even with capital, because the real edge sits in the process and tacit talent, not just the facility.
Organization
AquaBounty Technologies, Inc. showed it can design and run contained production sites, including its Ohio recirculating aquaculture system facility, with 2023 revenue of $0.9 million and a net loss of $60.4 million. That operating know-how supported broodstock, hatchery, egg, and fry production, but the company’s scaled production base remained limited.
Competitive Advantage
AquaBounty Technologies, Inc.’s broodstock, hatchery, egg, and fry production gave it a temporary competitive advantage because it controlled a rare GMO salmon breeding and early-life production process, which was hard to copy quickly. But that edge was not durable: the business still faced heavy losses, weak scale, and financing stress, and its commercial salmon push was wound down by 2024.
Rare hatchery edge faded as AquaBounty hit $0 revenue and deep losses
AquaBounty Technologies, Inc.'s broodstock and hatchery capability was valuable and rare, but by 2024 the edge had faded as the company wound down commercial salmon work. It reported 2024 revenue of $0 and a net loss of $45.5 million, showing the asset base did not scale into a durable advantage.
| Metric | Value |
|---|---|
| 2024 revenue | $0 |
| 2024 net loss | $45.5M |
Vertical integration across the salmon value chain
Value
AquaBounty Technologies, Inc.’s value comes from its patented AquaAdvantage salmon trait, which lets fish reach market size in about 18 months versus about 36 months for conventional Atlantic salmon. That IP edge has been the core of premium differentiation and a barrier to imitation across the salmon chain.
Rarity
Fish-biotech approvals are rare and slow, which makes AquaBounty Technologies, Inc. more defensible than pure farm operators. The U.S. FDA’s AquaAdvantage salmon won approval in 2015 after about 20 years of review, showing how hard it is to copy a vertically integrated salmon platform with genetics, hatchery, grow-out, and approvals.
Imitability
AquaBounty Technologies, Inc. vertical integration is hard to copy because it blends genetics, hatchery control, feed, and land-based farming, and that needs scarce know-how plus years of capital spend. In 2023, AquaBounty sold its Indiana farm for $9.5 million, showing how expensive and hard to scale this model is.
That makes the value chain imitation challenge high, since a rival would need the same specialized team, process data, and sustained funding before matching output or cost discipline.
Organization
AquaBounty Technologies, Inc. has direct know-how in designing and running contained production facilities, which supports Organization in its vertical salmon chain. In its 2025 filings, the Company reported cash of about $0.3 million and a going-concern warning, so this capability is real but under severe financial strain.
That operating history still helps the Company coordinate breeding, grow-out, and biosecurity controls, but it does not by itself make the resource durable.
Competitive Advantage
AquaBounty Technologies, Inc. used vertical integration across broodstock, hatchery, farming, and sales to control quality and traceability, but the edge was temporary because the model was not scaled into durable profits. In FY2025, the company was still in a restructuring phase, so the integration did not translate into a lasting moat.
Integrated, But Financially Fragile: AquaBounty's FY2025 Reality
AquaBounty Technologies, Inc. built value through vertical control of broodstock, hatchery, farming, and sales, but the edge was not durable. In FY2025, cash was about $0.3 million and the Company carried a going-concern warning, so the integrated model stayed strategic but financially fragile.
| FY2025 metric | Value |
|---|---|
| Cash | $0.3 million |
| Status | Going-concern warning |
Biosecurity and fish-health management
Value
AquaBounty Technologies, Inc.'s proprietary growth gene and patent shield make biosecurity and fish-health control valuable because they protect the fast-growing salmon trait and the premium pricing it supports. The U.S. FDA approved AquAdvantage salmon in 2015, and AquaBounty’s 2024 filings show the business still depends on IP protection to keep that trait hard to copy.
Rarity
Biosecurity and fish-health management is rare for AquaBounty Technologies, Inc. because fish-biotech approvals are unusually scarce and slow; AquaBounty Technologies, Inc.'s AquAdvantage salmon took about 20 years to win FDA approval in 2015. That long, costly path shows why few rivals can match the same regulatory and health-control setup.
Imitability
AquaBounty Technologies, Inc.’s biosecurity and fish-health management is hard to copy because it relies on specialized staff, long-running health data, and constant investment in monitoring and containment. Competitors can buy similar gear, but not the accumulated know-how, which is why this capability stays rare and costly to replicate.
Organization
AquaBounty Technologies, Inc. has real know-how in designing and running contained production facilities, which supports tight biosecurity and fish-health control. Its recirculating aquaculture system model is built to reduce pathogen exposure and keep fish in a controlled environment, so this capability is valuable and hard to copy.
Competitive Advantage
In 2025, AquaBounty Technologies, Inc. uses strict biosecurity and fish-health controls to reduce disease risk and protect yield, which supports a temporary competitive advantage. But these systems are costly to copy and can be matched by larger salmon producers, so the edge is real but not durable.
AquaBounty’s Rare Biosecurity Edge
AquaBounty Technologies, Inc.'s biosecurity and fish-health management stays valuable because its contained RAS sites protect yield and the AquAdvantage trait; the FDA approved the salmon in 2015 after about 20 years of review. It is rare and hard to copy because the control setup depends on specialized know-how and long operating data.
| Metric | Data |
|---|---|
| FDA approval | 2015 |
| Review time | ~20 years |
| System | RAS containment |
Science-based brand and first-mover reputation
Value
AquaBounty Technologies, Inc.'s AquAdvantage Salmon got FDA approval in 2015, giving the company first-mover credibility in genetically engineered food fish. Its patented fast-growth trait, built from a Chinook salmon growth gene and an ocean pout promoter, supports premium positioning and keeps rivals from copying the trait outright.
Rarity
Fish-biotech approvals are rare and slow, which makes AquaBounty Technologies, Inc.’s science-based brand hard to copy. AquaAdvantage salmon took about 20 years to win FDA approval in 2015, and Canada followed in 2016; that kind of regulatory moat is unusual in aquaculture, where only a handful of engineered-animal approvals exist.
Imitability
AquaBounty Technologies, Inc.’s science-based brand is hard to copy because rivals need specialist genetics talent, long test cycles, and heavy capital; the company spent years building its fast-growing salmon platform and FDA-approved know-how. Its first-mover edge is still tied to scarce data, regulatory skill, and large fixed costs that most fish farmers won’t fund.
Organization
AquaBounty Technologies, Inc. built a science-based brand and first-mover edge by designing and running contained production sites, including its 100,000-plus-square-foot recirculating aquaculture facility in Albany, Indiana. That operating know-how is rare and hard to copy, even as the company reported just $0.2 million of revenue in 2024, showing the asset is more strategic than scalable in the near term.
Competitive Advantage
AquaBounty Technologies, Inc. built a science-based brand as the first company to sell genetically engineered salmon in the U.S., but that edge is temporary. In FY2025, its weak scale and ongoing losses showed that the brand and first-mover status have not turned into a lasting moat.
AquaBounty’s First-Mover Edge Hasn’t Translated Into Real Scale
AquaBounty Technologies, Inc. has a science-based brand, but its edge is narrow: it was the first company to sell genetically engineered salmon in the U.S., after FDA approval in 2015 and Canada in 2016. The moat is hard to copy, yet FY2024 revenue was only $0.2 million, so first-mover status has not scaled into durable power.
| Key point | Data |
|---|---|
| FDA approval | 2015 |
| Canada approval | 2016 |
| FY2024 revenue | $0.2 million |
North American commercial relationships and market access
Value
AquaBounty Technologies, Inc. holds a strong North American value edge because its patented fast-growing salmon trait and related gene IP protect premium differentiation; the Company’s AquAdvantage salmon remains the only FDA-approved genetically engineered animal for food and was also approved for sale in Canada. That gives AquaBounty Technologies, Inc. a rare market-access moat in 2 key North American markets.
Rarity
Rarity is high because fish-biotech approvals are still unusual and slow: AquaBounty Technologies, Inc. won the first FDA approval for a genetically engineered animal for food in 2015, and Canada followed in 2016. That makes North American market access scarce; in the U.S. there has still been just one approved GM fish for human food.
Imitability
North American commercial relationships and market access at AquaBounty Technologies, Inc. are hard to copy because they rely on specialized sales talent, regulatory know-how, and steady investment in supply-chain and customer data. In 2025, that kind of moat is not built fast; rivals still need years of trust-building to match it.
Organization
AquaBounty Technologies, Inc. had real organization strength from its experience designing and operating contained production facilities, which lowered execution risk in regulated aquaculture. That matters in North American market access because the company already knew the permits, biosecurity controls, and site workflows needed to run indoor systems at commercial scale.
Competitive Advantage
AquaBounty Technologies, Inc. has North American market access through FDA and Health Canada approvals for AquAdvantage Salmon, but the edge is temporary because rivals can copy distribution and farming gains. With small operating scale and limited commercial reach in 2025, its customer ties help, but they do not create a durable moat.
AquaBounty’s Rare FDA Moat: The Only Approved GM Fish in North America
AquaBounty Technologies, Inc. has a rare North American access moat: AquAdvantage Salmon remains the only FDA-approved genetically engineered animal for food and was approved in Canada, too. That regulatory edge supports market access, but with limited scale in 2025, the edge is valuable yet not durable.
| Metric | 2025/2026 |
|---|---|
| FDA approval | 2015 |
| Canada approval | 2016 |
| Approved GM fish for food in U.S. | 1 |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.